News

Reverdia starts its bio-succinic acid plant
Enlarge image

BusinessItalyNetherlandsFrance

Reverdia starts its bio-succinic acid plant

17.12.2012 - Reverdia has started industrial production of bio-succinic acid at a new production plant with an annual capacity of 10,000 metric tons.

The joint venture between Dutch DSM NV and French starch producer Roquette Frères has begun operations in Cassano Spinola, Italy, at a commercial-scale plant producing Biosuccinium™ sustainable succinic acid. The company said the plant, which has a capacity of about 10,000 tonnes/yr, was unique in its kind, being the world’s first dedicated large-scale plant for the production of succinic acid from renewable resources. However, according to US-based BioAmber Inc, which fused BioAmber SAS and US company DNP Green Technology in 2010, it has been producing the chemical building block at 4,000 tonnes/yr since 2009.

Both producers rely on genetically engineered E.coli strains for producing the compound, that is being used to make bioplastics, chemical internmediates such as 1,4 butanediol, solvents, coatings, and phthalate-free plasticisers. As the market for bio-based succinic acid is expected to grow rapidly in the next few years, other joint-ventures such as Succinity or US-based Myriant Inc. are building production facilities. Reverdia will market its bio-succinium in collaboration with Helm.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/reverdia-starts-its-bio-succinic-acid-plant.html

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.75%
  • DIAXONHIT (F)0.79 EUR14.49%

FLOP

  • ZELTIA (E)3.69 EUR-8.44%
  • SWEDISH ORPHAN BIOVITRUM (S)13.05 USD-6.12%
  • ALMIRALL (E)17.75 EUR-5.84%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • IXICO (UK)34.00 GBP44.7%
  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.8%

FLOP

  • BIOTEST (D)25.52 EUR-64.1%
  • BIOTECH PHARMACON (N)9.45 NOK-44.7%
  • TRANSGENE (F)2.87 EUR-23.5%

TOP

  • ADOCIA (F)86.78 EUR577.4%
  • FORMYCON (D)28.39 EUR323.1%
  • DBV TECHNOLOGIES (F)79.24 EUR317.5%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.10 SEK-70.6%
  • NEOVACS (F)1.02 EUR-68.6%

No liability assumed, Date: 31.07.2015